2023 European Liver Annual Conference: Scientific Researchers Commenting on the Prospects of Cisplatin Targeted Immunotherapy AB359

Tech 2023-07-07 21:42:41 Source: Network

At the first meeting of the European Liver Conference in 2023, Professor Matteo Iannacone from the Scientific Research Institute in Santa Fe, Italy, described AB359, a new preclinical in vivo trial data that further supports AB359 as a promising innovative immunotherapy for treating chronic HBV. The core content of this data is as follows:This study refers to selectively activating the IL-2 pathway in CD8+T cells to drive antiviral activity against hepatitis B virus (HBV)

At the first meeting of the European Liver Conference in 2023, Professor Matteo Iannacone from the Scientific Research Institute in Santa Fe, Italy, described AB359, a new preclinical in vivo trial data that further supports AB359 as a promising innovative immunotherapy for treating chronic HBV. The core content of this data is as follows:

This study refers to selectively activating the IL-2 pathway in CD8+T cells to drive antiviral activity against hepatitis B virus (HBV). The mouse substitute for AB359 (muAB359) showed convincing antiviral activity in the HBV mouse model, which reproduced the key features of CD8+T cell dysfunction observed in chronic HBV infected individuals. A single dose of muAB359 could significantly reduce the levels of two key markers in the HBV infection model, which showed that the serum HBV core DNA decreased by more than 100 times, and the serum hepatitis B surface antigen decreased by 79%;

Commentary from Dr. Ivana Djuretic, Founder and Chief Scientific Officer of AsherBio: It is a pleasure to share the new preclinical data of AB359, which highlights the promising candidate drug advantages of our cis targeting platform in a wide range of therapeutic fields, especially our ability to develop promising candidate drugs for differentiated cytokine therapy for the treatment of infectious diseases.

In the case of chronic HBV, our goal is to selectively increase the number and function of CD8+T cells, which are known to be involved in clearing viral infections, while avoiding the pleiotropic clinical application of IL-2 basic therapies that have historically limited their widespread effects. The new data released at the 2023 European Liver Conference shows that using our molecular therapy can significantly activate HBV specific CD8+T cells, leading to a significant decrease in key markers of HBV infection.

Based on these data, we believe that AB359 improves existing anti HBV therapies, which are only applicable to some patients and have a low cure rate. We are seeking opportunities to collaborate with companies with the necessary expertise and capabilities in hepatitis drug development to support the development of AB359, with the goal of developing a new type of chronic HBV immunotherapy, which is a major health burden affecting 250 million people worldwide.

Conclusion of Xiaofan Health: Yesterday, we introduced the new preclinical research data of AB359 at this European Liver Conference. Today, we will introduce the core conclusions and future development prospects of this new data. It is a novel immunotherapy in the preclinical research stage aimed at selectively activating CD8+effector T cells, thereby providing the potential to enhance the immune response to chronic viral infections (including HBV).

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: 2023 European Liver Annual Conference Scientific Researchers Commenting on